Madrigal Pharmaceuticals (MDGL) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Madrigal Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$958.40M

Latest Revenue (Q)

$364.25M

Main Segment (Y)

Reportable Segment

Madrigal Pharmaceuticals Revenue by Period

Madrigal Pharmaceuticals Revenue by Year

Date	Revenue	Change
2025-12-31	$958.40M	432.05%
2024-12-31	$180.13M	100.00%
2023-12-31	-	100.00%
2022-12-31	-	100.00%
2021-12-31	-	100.00%
2020-12-31	-	100.00%
2019-12-31	-	100.00%
2018-12-31	-	100.00%
2017-12-31	-	100.00%
2016-12-31	-	100.00%
2015-12-31	-	100.00%
2014-12-31	-	100.00%
2013-12-31	-	100.00%
2012-12-31	-	-100.00%
2011-12-31	$7.58M	-48.77%
2010-12-31	$14.80M	-89.74%
2009-12-31	$144.25M	5416.06%
2008-12-31	$2.62M	251.95%
2007-12-31	$743.00K	100.00%
2006-12-31	-	100.00%
2005-12-31	-	-100.00%
2004-12-31	$173.00K	-86.73%
2003-12-31	$1.30M	100.00%
2002-12-31	-	100.00%
2001-12-31	-	-

Madrigal Pharmaceuticals generated $958.40M in revenue during NA 2025, up 432.05% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Madrigal Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2026-06-30	$364.25M	17.00%
2026-03-31	$311.34M	-3.04%
2025-12-31	$321.08M	11.77%
2025-09-30	$287.27M	34.99%
2025-06-30	$212.80M	55.05%
2025-03-31	$137.25M	32.84%
2024-12-31	$103.32M	66.18%
2024-09-30	$62.17M	324.75%
2024-06-30	$14.64M	100.00%
2024-03-31	-	100.00%
2023-12-31	-	100.00%
2023-09-30	-	100.00%
2023-06-30	-	100.00%
2023-03-31	-	100.00%
2022-12-31	-	100.00%
2022-09-30	-	100.00%
2022-06-30	-	100.00%
2022-03-31	-	100.00%
2021-12-31	-	100.00%
2021-09-30	-	100.00%
2021-06-30	-	100.00%
2021-03-31	-	100.00%
2020-12-31	-	100.00%
2020-09-30	-	100.00%
2020-06-30	-	100.00%
2020-03-31	-	100.00%
2019-12-31	-	100.00%
2019-09-30	-	100.00%
2019-06-30	-	100.00%
2019-03-31	-	100.00%
2018-12-31	-	100.00%
2018-09-30	-	100.00%
2018-06-30	-	100.00%
2018-03-31	-	100.00%
2017-12-31	-	100.00%
2017-09-30	-	100.00%
2017-06-30	-	100.00%
2017-03-31	-	100.00%
2016-12-31	-	100.00%
2016-09-30	-	100.00%
2016-06-30	-	100.00%
2016-03-31	-	100.00%
2015-12-31	-	100.00%
2015-09-30	-	100.00%
2015-06-30	-	100.00%
2015-03-31	-	100.00%
2014-12-31	-	100.00%
2014-09-30	-	100.00%
2014-06-30	-	100.00%
2014-03-31	-	100.00%
2013-12-31	-	100.00%
2013-09-30	-	100.00%
2013-06-30	-	100.00%
2013-03-31	-	100.00%
2012-12-31	-	100.00%
2012-09-30	-	100.00%
2012-06-30	-	-100.00%
2012-03-31	$147.00K	-95.71%
2011-12-31	$3.42M	105.71%
2011-09-30	$1.66M	22.90%
2011-06-30	$1.35M	18.46%
2011-03-31	$1.14M	-71.69%
2010-12-31	$4.04M	19.33%
2010-09-30	$3.38M	0.68%
2010-06-30	$3.36M	-16.48%
2010-03-31	$4.02M	-14.04%
2009-12-31	$4.68M	-96.41%
2009-09-30	$130.41M	2704.41%
2009-06-30	$4.65M	3.10%
2009-03-31	$4.51M	609.12%
2008-12-31	$636.00K	-50.00%
2008-09-30	$1.27M	-4.93%
2008-06-30	$1.34M	-
2008-03-31	$1.34M	100.00%
2007-12-31	-	-

Madrigal Pharmaceuticals generated $364.25M in revenue during Q2 2026, up 17.00% compared to the previous quarter, and up 265.39% compared to the same period a year ago.

Madrigal Pharmaceuticals Revenue Breakdown

Madrigal Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25
Reportable Segment	$958.40M

Madrigal Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Reportable Segment (100.00%).

Quarterly Revenue by Product

Product/Service	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25
Reportable Segment	$364.25M	$311.34M	$458.33M	$287.27M	$212.80M

Madrigal Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 26: Reportable Segment (100.00%).

Madrigal Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
JAZZ	Jazz Pharmaceuticals	$4.27B	$1.21B
BMRN	BioMarin Pharmaceutical	$3.22B	$989.71M
EXEL	Exelixis	$2.32B	$628.69M
MRNA	Moderna	$1.94B	$145.00M
TECH	Bio-Techne	$1.22B	$295.88M
MDGL	Madrigal Pharmaceuticals	$958.40M	$364.25M
BAX	Baxter	$352.00M	$2.96B
CAI	Caris Life Sciences	$294.01M	$263.71M
RYTM	Rhythm Pharmaceuticals	$189.76M	$71.25M
RNA	Atrium Therapeutics	$18.75M	$12.47M
ABVX	Abivax	-	-

MDGL Revenue FAQ

What is Madrigal Pharmaceuticals’s yearly revenue?

Madrigal Pharmaceuticals's yearly revenue for 2025 was $958.4M, representing an increase of 432.05% compared to 2024. The company's yearly revenue for 2024 was $180.13M, representing an increase of 100.00% compared to 2023. MDGL's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022.

What is Madrigal Pharmaceuticals’s quarterly revenue?

Madrigal Pharmaceuticals's quarterly revenue for Q2 2026 was $364.25M, a 17.00% increase from the previous quarter (Q1 2026), and a 71.17% increase year-over-year (Q2 2025). The company's quarterly revenue for Q1 2026 was $311.34M, a -3.04% decrease from the previous quarter (Q4 2025), and a 126.84% increase year-over-year (Q1 2025). MDGL's quarterly revenue for Q4 2025 was $321.08M, a 11.77% increase from the previous quarter (Q3 2025), and a 210.77% increase year-over-year (Q4 2024).

What is Madrigal Pharmaceuticals’s revenue growth rate?

Madrigal Pharmaceuticals's revenue growth rate for the last 3 years (2023-2025) was 0%, and for the last 5 years (2021-2025) was 0%.

What are Madrigal Pharmaceuticals’s revenue streams?

Madrigal Pharmaceuticals's revenue streams in c 25 are Reportable Segment

What is Madrigal Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Madrigal Pharmaceuticals was Reportable Segment. This segment made a revenue of $958.4M, representing 100.00% of the company's total revenue.